Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT02563197
NCT02563197CompletedPhase 1

An Open, Multi-center Study to Measure Inhaled Flow Rates Generated by Non-CF Bronchiectasis Patients for the T-326 Inhaler

Bayer10 sites in 1 country33 target enrollmentStarted: November 23, 2015Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Status
Completed
Sponsor
Bayer
Enrollment
33
Locations
10
Primary Endpoint
Peak inspiratory flow (L/min)
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Study should show feasibility of the device for drug delivery into the lung independently of the severity of impaired lung function.

Detailed Description

The aim of the study is to measure inspiratory profiles of patients with non-Cystic fibrosis bronchiectasis using the breath activated T-326 Inhaler.

The following parameters will be derived from the inspiratory profiles:

  • Peak Inspiratory Flow (PIF, in L/min)
  • Inspiratory Volume (V, in L)
  • Inspiratory Time (t, in s).

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Established diagnosis of non-cystic fibrosis bronchiectasis, confirmed and documented by high resolution computed tomography (HRCT) or magnetic resonance tomography (MRT)
  • •Ability to reproducibly perform spirometry according to American Thoracic Society/European Respiratory Society criteria
  • •Clinically stable in the opinion of the investigator at the time of the study visit.
  • •Male and female patients ≥ 18 years of age.

Exclusion Criteria

  • •Pulmonary exacerbation (as judged by the investigator, based on the clinical condition of the subject and taking into account e.g., febrile infection of the lung, relevant decrease in Forced expiratory volume in the first second (FEV1) value, increased sputum production, sputum purulence, recent hospitalization) at study visit or within the preceding six (6) weeks.
  • •History of lung transplant.
  • •Recent significant hemoptysis (≥ 300 mL or requiring blood transfusion) in the preceding six (6) weeks before screening.
  • •Established diagnosis of bronchial asthma.
  • •Established diagnosis of cystic fibrosis.
  • •Proof of any relevant medical finding or disease in the last three (3) months which might interfere with participation in the study or patient safety (e.g. pneumothorax, uncontrolled hypertension, uncontrolled cardiac arrhythmia, myocardial infarction, cerebral vascular accident).
  • •A relevant disease that is considered to interfere with the study results is any disease that, except for the impairment of lung function, interferes with the patient's ability to inhale from the device. For example, COPD per se is usually not considered as a reason for patient exclusion, unless coughing or obliteration of the upper airways with sputum interferes with the patient's ability to inhale from the device.
  • •Relevant surgical history in the last 3 months (e.g., but not limited to abdominal, thoracic, ocular or brain surgery).
  • •History or evidence of lung resection, thoracotomy, known aneurysm and severe scoliosis.
  • •Pregnancy.

Outcomes

Primary Outcomes

Peak inspiratory flow (L/min)

Time Frame: Visit 2 (1-14 days after screening visit 1)

Secondary Outcomes

  • Inspiratory volumes (V in L)(Visit 2 (1-14 days after screening visit 1))
  • Inspiratory time (t in s)(Visit 2 (1-14 days after screening visit 1))

Investigators

Sponsor
Bayer
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (10)

Loading locations...

Similar Trials

Completed
Not Applicable
Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIsPulmonary Disease, Chronic Obstructive
NCT03114969GlaxoSmithKline450
Terminated
Phase 2
Acute Effects of Inhaled Treprostinil in Fontan PatientsCongenital Heart Disease
NCT02769624Children's Hospital Medical Center, Cincinnati15
Completed
Not Applicable
COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder InhalersCOPD Exacerbation
NCT02291016University of Tennessee Graduate School of Medicine7
Unknown
Not Applicable
Clinical and Medico-economic Validation of the HEPHAI Solution.Asthma COPD
NCT06099145Hephai238
Terminated
Phase 2
Trimodal Lung-Sparing Treatment of Pleural MesotheliomaPleural Mesothelioma
NCT00859495Columbia University9